HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lyubchenko, T. Articles by Holers, V. M. Search for Related Content PubMed PubMed Citation Articles by Lyubchenko, T. Articles by Holers, V. M.

Coligation of the B Cell Receptor with Complement Receptor Type 2 (CR2/CD21) Using Its Natural Ligand C3dg: Activation without Engagement of an Inhibitory Signaling Pathway¹

Taras Lyubchenko^2,*, Joe Dal Porto, John C. Cambier and V. Michael Holers^*,

Departments of ^* Medicine and Immunology, University of Colorado Health Sciences Center, Denver, CO; and Department of Immunology, National Jewish Medical and Research Center, Denver, CO

C3dg is a cleavage product of the C3 component of complement that can facilitate the coligation of the complement receptor 2 (CR2/CD21) with the BCR via C3dg/Ag complexes. This interaction can greatly amplify BCR-mediated signaling events and acts to lower the threshold for B cell activation. Although previous studies have used anti-CR2 Abs or used chimeric Ags in the context of BCR transgenic mice as surrogate C3d-containing ligands, we have used a physiological form of C3d to study signaling in B cells from wild-type C57BL/6 mice. We find that while CR2-enhanced BCR signaling causes intracellular Ca²⁺ mobilization and total pTyr phosphorylation of an intensity comparable to optimal BCR ligation using anti-IgM Abs, it does so with limited activation of inhibitory effectors (such as CD22, Src homology region 2 domain containing phosphatase 1, and SHIP-1) and without substantial receptor cross-linking. In summary, we demonstrate that CR2-enhanced BCR signaling may proceed not only through the previously described amplification of positive signaling pathways, but is potentially augmented by a lack of normal inhibitory/feedback signaling.

This article has been cited by other articles:

				T. Lyubchenko, J. M. Dal Porto, V. M. Holers, and J. C. Cambier Cutting Edge: Complement (C3d)-Linked Antigens Break B Cell Anergy J. Immunol., September 1, 2007; 179(5): 2695 - 2699. [Abstract] [Full Text] [PDF]

				R. Asokan, J. Hua, K. A. Young, H. J. Gould, J. P. Hannan, D. M. Kraus, G. Szakonyi, G. J. Grundy, X. S. Chen, M. K. Crow, et al. Characterization of Human Complement Receptor Type 2 (CR2/CD21) as a Receptor for IFN-{alpha}: A Potential Role in Systemic Lupus Erythematosus J. Immunol., July 1, 2006; 177(1): 383 - 394. [Abstract] [Full Text] [PDF]

				Y. Lee, K. M. Haas, D. O. Gor, X. Ding, D. R. Karp, N. S. Greenspan, J. C. Poe, and T. F. Tedder Complement Component C3d-Antigen Complexes Can Either Augment or Inhibit B Lymphocyte Activation and Humoral Immunity in Mice Depending on the Degree of CD21/CD19 Complex Engagement J. Immunol., December 15, 2005; 175(12): 8011 - 8023. [Abstract] [Full Text] [PDF]

				P. K. A. Mongini, J. K. Inman, H. Han, S. L. Kalled, R. J. Fattah, and S. McCormick Innate Immunity and Human B Cell Clonal Expansion: Effects on the Recirculating B2 Subpopulation J. Immunol., November 1, 2005; 175(9): 6143 - 6154. [Abstract] [Full Text] [PDF]